GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (XSWX:CURN) » Definitions » Capex-to-Operating-Cash-Flow

Curatis Holding AG (XSWX:CURN) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Curatis Holding AG Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Curatis Holding AG's Capital Expenditure for the six months ended in Jun. 2024 was CHF0.00 Mil. Its Cash Flow from Operations for the six months ended in Jun. 2024 was CHF-0.56 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Curatis Holding AG Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Curatis Holding AG's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG Capex-to-Operating-Cash-Flow Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
- - -

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of Curatis Holding AG's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curatis Holding AG's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Curatis Holding AG's Capex-to-Operating-Cash-Flow falls into.


;
;

Curatis Holding AG Capex-to-Operating-Cash-Flow Calculation

Curatis Holding AG's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -1.885
=N/A

Curatis Holding AG's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.559
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curatis Holding AG  (XSWX:CURN) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Curatis Holding AG Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Curatis Holding AG's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Curatis Holding AG Business Description

Traded in Other Exchanges
Address
Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.